N-ECCO School © ECCO

At the 20th Congress of ECCO in Stockholm, the Nurses of ECCO (N-ECCO) will host the educational activity for IBD Nurses, N-ECCO School, for the 16^th time. ECCO intends to give nurses, who might be still in training and have an interest in IBD, the possibility to attend an IBD-focused course. The ultimate aim of this programme is to improve nurse education throughout Europe.

The Educational Programme of the 20^th Congress of ECCO starts prior to the official start of the ECCO Congress and courses take place from February 19-21, 2025. These activities target ECCO’s different interest groups including young gastroenterologists, surgeons, paediatricians, pathologists, IBD Nurses, dietitians, allied health professionals and scientists.

To submit an abstract for the 20th Congress of ECCO, use our ECCO Portal. Please also view important information on the submission process and the guidelines for abstract submission.

ECCO convenes a bi-annual National Representatives Meeting, providing a platform for IBD stakeholders including National representatives from IBD, nurse and patient organisations to discuss ECCO’s activities, highlight their positions and strategize in the context of Diversity, Equitable Access and Inclusion.

On the occasion of the UEG Week 2023 in Copenhagen, ECCO hosted the 3rd Council of National Representatives Meeting – bringing together the ECCO and N-ECCO National Representatives as well as the National Representatives of Patient Organisations and EFCCA.

Britta Siegmund © ECCO

Dear ECCO Friends,

Summer is coming and Berlin is getting ready – not yet for the next ECCO Congress, but for the European Soccer Championship! Leading up to the summer break, everyone has been very active, which is reflected in this issue of ECCO News.

UR-CARE is now established in many centres across Europe and I would like to take this opportunity to welcome Gerhard Rogler as the new chair of the UR-CARE Steering Committee! If you would like to learn more about the plans and activities around UR-CARE, enjoy the interview with Gerhard.

Nutritional therapy has been proven to be a safe and effective treatment for Inflammatory Bowel Disease (IBD), including Crohn’s Disease (CD). Nutritional approaches can help induce and maintain remission, either as a standalone therapy or in combination with other treatments.

New research continues to expand the understanding of which patients would benefit most from dietary therapy, and the best approach to implementing it.

Dear ECCO Friends,

Welcome to this new episode of the Meet the JCC Authors Podcast!

Here, we interview the rising star of intestinal ultrasound (IUS), Michael Dolinger from Mount Sinai Hospital (NY, US), about his recent article in JCC entitled: “Early intestinal ultrasound response to biologic therapy predicts endoscopic remission in children with ileal Crohn's Disease: Results from the Prospective Super Sonic Study”.

We discuss the increasing use of IUS as a tool to predict response to therapies in treat-to-target strategies in both children and adults and how it can identify those patients who will achieve endoscopic remission. In addition, we talk about Michael’s journey and the introduction of IUS in the United States, the learning curves, the future of IUS in IBD, new technologies and much more.

We hope you enjoy it!

Ignacio Catalan-Serra
ECCO News Associate Editor

Robin Dart © ECCO

For this Y-ECCO Interview Corner we met with Shaji Sebastian, who is known to everyone as Seb, on the Friday of the ECCO Congress. Seb has had a long association with ECCO. He is the outgoing Chair of ClinCom and was elected as Treasurer of ECCO at this year’s General Assembly. He is a consultant in Hull in the North of England, having got there through a somewhat circuitous route, as we will hear...

Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn’s Disease (EXPLORER)

Colombel JF, Ungaro RC, Sands BE, et al.

Clin Gastroenterol Hepatol 2023. doi: 10.1016/j.cgh.2023.09.010. Online ahead of print.

Introduction

The SONIC trial yielded seminal findings showing that the combination of infliximab and azathioprine is more effective than either treatment alone for the maintenance of remission in patients with Crohn’s Disease (CD) [1]. In recent years, despite the availability of an increasing number of biologics and small molecules to treat CD, a ceiling of therapeutic efficacy has been reached [2]. Therefore, there has been a resurgence of interest in whether this therapeutic ceiling “effect” can be overcome with new treatment combinations. In the EXPLORER study, the efficacy and safety of triple combination therapy was assessed using two biologics with different modes of action in association with methotrexate for the treatment of CD.

Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: Results of the Constellation Study

Yarur A, Bruss A, Moosreiner A, et al.

Gastroenterology 2023;165:963–75

Introduction

Despite an expanding therapeutic arsenal, a considerable proportion of patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) fail to achieve or sustain therapeutic responses [1, 2]. Mechanisms contributing to this failure, particularly with respect to biologic therapy, are only partially understood [3]. Uncovering the mechanisms behind loss of response may help to enhance the efficacy of existing treatment options or to develop alternative options for the future.

Some investigations have noted an association between obesity, high intra-abdominal visceral adipose tissue (IA-VAT) mass and unfavourable outcomes in individuals with Inflammatory Bowel Disease (IBD). However, these observations have been constrained by their methodology and have to date focused only on patients having treatment with anti-tumour necrosis factor alpha (anti-TNF-α) agents [4–6], limiting their scope.

The Constellation Study by Yarur and colleagues aimed to investigate the relationship between IA-VAT in patients with IBD and the response to biologic drugs with multiple different mechanisms of action.